Alpha-synuclein, TDP-43 signatures, and cerebral small vessel disease were common in people with discordant stages. Older ...

The FDA has cleared the first blood test to diagnose Alzheimer's which works by measuring the amount of pTau 217 and ...

The four blood-marker-based stages (0 to 3 from left to right) correlated well with neurofibrillary tangle accumulation ... Salvadó tested this scheme on 222 CSF samples from the Knight Alzheimer ...

The Lumipulse blood test identifies the presence of amyloid plaques, a hallmark of Alzheimer’s disease that impairs normal ...

The symptoms change according to the stage of the disease. In later stages, people with Alzheimer’s often have significant trouble with talking, moving, and responding to what’s happening ...

According to the Alzheimer’s Association, out of the nearly 7 million people aged 65 and older with Alzheimer’s dementia in the U.S., 4.2 million are women, while only 2.7 million are men.

The highly-anticipated readout from the Clarity AD has shown that lecanemab met primary and secondary endpoints in patients with early-stage Alzheimer's, said the ... seen in 21.3% and 9.3% ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli ...